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INTRODUCTION
In February 1991 a discussion paper by the NSW Health Department's Epidemiology
and Health Services Evaluation Branch (EHSEB) was completed which primarily
addressed the epidemiology of tuberculosis in NSW1• The paper included a review of
the international literature on methods of tuberculosis (TB) control, and compared the
methods used in NSW with those used in other parts of Australia, the United States
and Britain.
Key recommendations of this document were that the role and organisation of TB
Services in NSW be reviewed and that a strategy for NSW be developed which
addresses TB surveillance, screening, BCG vaccination, chemoprophylaxis, case follow
up and program evaluation. The NSW TB Advisory Committee also recommended that
a more in depth appraisal of the epidemiology of TB in NSW be undertaken.

l .

l A Review of TB Services in NSW has been prepared by the EHSEB and NSW TB

J Coordinator, concurrently with the development
j recommendations from the Review are that:

of

this

document.

Key

•

•

all active cases have treatment initiated and ceased by, and be
discharged from medical care by, a Specialist Physician at the nearest
Chest Clinic;

•

the NSW Infectious Diseases Surveillance System (IDSS) database be
expanded and be made accessible to Chest Clinics via computer networks
with Public Health Units, to facilitate surveillance of disease and
infection, patient management and program evaluation;

•

routine screening - of staff, contacts, old inactive cases and migrants on
Health Undertakings - in localities where Chest Clinic Sisters are not
based be undertaken by local hospital or Community Health staff;

•

Area/ Regional TB coordinators be responsible for routine program
evaluation and ensuring the implementation of Statewide policies and
guidelines;

•

the NSW TB Coordinator report to the NSW Health Department on TB
program indicators for the State;

•

updated State policies and guidelines for Mantoux testing, contact
tracing, migrant and refugee follow up, BCG vaccination and screening
of health care workers be distributed to NSW health services in a
'Policies and Procedures Manual'; and

•

consensus guidelines be developed, through consultation with clinicians,
related to first line drug regimens and indications for chemoprophylaxis,
the role of supervised chemotherapy and duration of case followup.
1

if
'

Recommendations from the 1991 discussion paper and the 1992 Review of TB Services
have been incorporated into this Strategy for the Control of TB in NSW.

•

evaluating the effectiveness of interventions: eg although the
efficacy of modern treatment regimens under controlled trial
conditions is well established, there are few data available on the
effectiveness and efficiency of treatment under routine conditions
in low incidence countries.

•

program planning: Program evaluation, research and monitoring
of epidemiological trends should guide program plauning, eg
screening programs should be regularly evaluated to assess their
worth, as screening is generally recommended only where the rate
of infection is greater than one per cent4 •

•

patient management: In the case of TB few data beyond those
necessary for patient management are required for routine
program evaluation.

This document addresses four major methods of TB control: disease containment, case
prevention, surveillance and program evaluation.

•

Disease containment
Early identification and adequate treatment of cases of infectious TB are
the most important measures to prevent spread of the disease. The
major obstacle to disease containment is the interruption of and/ or
failure to complete therapy with an appropriate drug regimen2 • The two
main causes of treatment failure are inappropriate combinations of
drugs, dosages and duration and poor compliance (due to inadequate
supervision or communication and social or medical host factors such as
alcohol, drugs, poor nutrition, homelessness).

•

Case prevention
The main case prevention strategy is screening for, and treatment of, TB
infection in high risk groups. No matter how efficient case finding,
diagnosis and treatment are, the development of disease in those already
infected can only be prevented by appropriate chemoprophylaxis3 • The
associated risks - side effects and possible emergence of drug resistant
strains - must be weighed against the potential benefits.

•

Surveillance
Timely identification and notification of confirmed and suspected cases
facilitates early treatment and preventive intervention. Surveillance is
essential for estimating incidence, distribution and trends of disease and
infection and for plauning services rationally. In low incidence countries,
the number and trends in bacteriologically positive cases is the most
useful parameter of the epidemiology of TB. The risk of infection is only
a useful indicator with large sample sizes which provide reliable
estimates. Infection surveillance requires careful strategic planning of
screening in high risk populations.

•

Program evaluation
The monitoring of parameters related to disease containment, case
prevention and surveillance activities provides important information for:

111

•

evaluating program performance

•

assessing epidemiological trends: eg the incidence of
Mantoux conversion in contacts reflects the rate of transmission
of TB in the population.

i:!

I,!
'

I

I:

I;

I
i

. This document has three parts. The first part provides an overview of the epidemiology
' of TB in NSW. The second part defines the goals, targets and implementation
· indicators for the NSW TB Control Strategy. The third part contains policies and
guidelines for TB Services, which were endorsed by a consensus meeting of Chest
Clinic Staff, Respiratory, Public Health and Infectious Disease Physicians in October,
1992.
The proposed implementation indicators - for each of the four control methods and for
TB Services themselves - are intended to provide strategic direction and a means of
monitoring progress towards attaining the goals and targets. Each implementation
indicator includes a timeline and the person(s) responsible for ensuring its
achievement.
This document does not attempt to review the current state of international knowledge
. of TB control. Such a review was the subject of the 1991 discussion paper and readers
should refer to that document1 • Recommendations from that review have been
incorporated into the strategies and policies.
The rationale behind the proposed implementation indicators and policies is that more
effective and efficient use of existing prevention and control methods and technologies
should lead to significant improvements in TB control.
The development of new preventive, diagnostic and treatment technologies will
expedite these improvements. Although not specifically addressed by this document,
the NSW Health Department and associated bodies, eg Institute for Clinical Pathology
and Medical Research (ICPMR), should encourage the development, evaluation and
implementation of rapid diagnostic techniques, improved screening methods, short
duration drug regimens and treatments for drug resistant strains. This research
should be undertaken in cooperation with the National Health and Medical Research
Council (NHMRC) and World Health Organization (WHO) sponsored programs.

r'
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1.
1.1

EPIDEMIOLOGY
Notifications of reactivated cases have continued to decline steadily from 0.6 per 100
OOO in 1979 to 0.3 in 1986 and 0.2 per 100,000 in 1991. The case load of reactivated
disease has also declined. In 1975 9.8% (51) of the notified cases of pulmonary disease
were reactivations5• In 1991 2.7% (eight) of notified cases of pulmonary disease were
reactivations. Of these eight reactivated cases, five were Australian born (all aged over
45), one was Asian born (aged 25-34) and two were born in Europe (both aged over 45).
(Until 1992 a reactivation was defined as a case of active TB who had previously
received a full course of treatment in NSW and been declared cured.)

ACTIVE DISEASE NOTIFICATION

In NSW 393 active TB cases were diagnosed and reported in 1991. Of these, nine
(2.3%) were cases of reactivated TB. Of 383 new cases, 289 (76%) had pulmonary
disease.

In NSW between 1963 and 1991 notifications of active disease declined from 30.5 to
6.5 per 100,000 for new cases and 3.5 to 0.15 per 100,000 for reactivated cases (Figure
{ In 1991, of the 260 new pulmonary cases for whom direct sputum smear results were
1). The notification rate of smear positive cases in 1991 was 2.8 per 100,000.
; recorded, 132 (51%) were smear positive. Smear negativity is more co=on in Asian
Moderate decreases occurred in notifications of new cases of TB in NSW in the early j born cases than Australian born cases", proportions having smear positive disease
1980s, froin a rate of 11.1 per 100,000 in 1979 to 5.2 per 100,000 in 1986. Between , being 58% and 48% respectively in 199L ·
1989 and 1991 there was a slight increase, from 5.8 new cases per 100,000 to 6.5 per
100,000.

ACTIVE TB f\OTIFICATIQ\JS BY SITE

F10 2:

The decline in new cases since 1963 is almost entirely accounted for by the decline in
new pulmonary disease from a rate of 28.7 to 4.9 per 100,000 in 1991 (Figure 2). ·'
Over the same period notifications of new extrapulmonary disease have ranged
between a maximum of 2.3 per 100,000 in 1973 and a minimum of 1.0 per 100,000 in I
1985. A moderate increase in notifications of new extrapulmonary disease has occurred J
since 1985. In 1991 the notification rate of new extrapulmonary disease was 1.6 per
100,000.

NSW - 1950-1991
70
60

rate I 100,000
.......•.•..•••..•.•....•..........•.•.....•....•..........•..........•.•.

·,1

70

50 •....••...•....•••..••...•••...•••..•••....••..••••.•.•••....•••..••••...••..
40

..........•...••.••...•.•....••...•••...•.....•..........•.•.....•.......•.

30

•••··•·•····••··•·••·•·

ACTIVE TB f\OTIFICATJ()\JS

20

NSN - 1950 - 1991

10

rate 1100,000

0

1950

1954

1958 1962

1966 1970 1974 1978
year

1982

1986

1991

60

...............•..•.......•..•..•.•..........•..•............•.....•....•....•

50

•....•....••...••••••..•••...•••....•••...••••.•...••.....••...•.••.•...•...••.•

40

..........•....•......•....•..•...••....•..•..•..•.•.....•....•.....•.•..•.....

30

•••······•····•••••··•••

20

•.••.....••....••••...••••...• •

1.2
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Mortality due to TB in Australia has fallen steadily this century5. This fall was
accelerated by the introduction of effective chemotherapy in about 1954. The majority
of deaths occur in the elderly, many of whom die with, rather than from, TB6 •
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The death rate from TB in NSW declined from 1.40 per 100,000 people in 1970 to 0.54
per 100,000 in 1988.
Over the period 1989 to 1991 less than 1% of all TB case notifications were from death
certification (ie 'delay of diagnosis until death').
5
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1.3

CENTRAL NERVOUS SYSTEM (CNS) DISEASE

1.6

For 1988/89 the incidence of TB CNS infections was 0.35 per 100,000 population. The
highest age specific incidence was in 35-44 year olds, being 1.4 per 100,000. Of the 20
cases with TB infection of the CNS, 12 (60%) were in the age group 35-44. There was
only one child aged less than five years with TB of the CNS.

1.4

RISK FACTORS

TB morbidity in a population depends upon the risk of infection and the risk of disease
following infection. One new TB case on average leads to less than one new infectious
case10 so rates of disease in a stable community should naturally decline.
Some groups have a higher incidence of TB than the general population due to a
higher prevalence of infection, or higher risk of developing the disease once infected.
Most new cases of TB arise from people with latent rather than new infections10• There
is often a long latent period between infection and development of TB. It is estimated
that more than 90% of people with disease have harboured TB infection for at least a
year; the remaining 10% have immediate progression of recently acquired infection11.

DRUG RESISTANCE RATES

Asian immigrants are considered at particular risk of harbouring drug resistant
tubercle bacilli because of the likelihood of inadequate, interrupted chemotherapy,
usually with one or two drugs, due to the high relative costs of anti-TB drugs in Asia".
High rates of drug resistance strains have also been reported overseas in those with
HIV-TB coinfection2 •

Age

In 1991 18 new TB cases (4.7%) were resistant to isoniazid, five (1.3%) were resistant The risk of TB infection is associated with increasing age in all races and in both
to rifampicin, 30 (7.8%) were resistant to streptomycin and one case (0.3%) was sexes10• The risk of progression to disease is highest in infants, young adults and the
resistant to ethambutol. Eight new cases were resistant to two drugs (Australian born: . elderly10•12• TB infection acquired in infancy and adolescence carries a high risk of
1, Asian born: 4, Middle East born: 3). Two new cases were resistant to three drugs
rapid progression to disease 13; if disease develops, a more serious form (for example
(Asian born: 2).
meningitis or miliary disease) is more likely to occur11• The lifetime risk of TB disease
for infected children is up to 10%' 0• The prevalence of disease generally rises steeply
Of the eight reactivated TB cases in 1991, only one was drug resistant. This case, who with age, particularly for bacteriologically proven disease". Persons over age 50 with
was Australian born, was resistant to two drugs. Of the 10 cases of TB-HIV unrecognised smear-positive disease are considered major public health risks".
coinfection, two were resistant to one drug and one was resistant to two drugs.
1991 NSW notifications show an increasing trend with age, with minor peaks in the
age groups 0-4 years and 25-44 years (Figure 3). The highest incidence is in those aged
1.5
· more than 65 with a rate of 13.7 per 100,000 for new cases and 0.6 per 100,000 for
INFECTION PREVALENCE AND INCIDENCE
reactivated cases.
Data on infection prevalence and incidence rates in subpopulations in NSW are
limited.
Fig

A recent survey of police recruits in NSW found a Mantoux positivity rate on
employment of 11%7 • In those who had not been previously BCG vaccinated the
Mantoux positivity rate was 7%. A Mantoux reaction of 5mm or more was considered a
positive result. Using a cut-off point for a positive reaction of 10mm or more, 4% of
those who had not previously received BCG vaccination were Mantoux positive. These
results are considered generalisable to the NSW population.
Preliminary results from a screening survey of Year 8 schoolchildren in Central/
Southern Sydney, an area with a high migrant population, show a Mantoux positivity
rate of more than 12%8 • In children who had had previous BCG vaccination a
Mantoux reaction of 15mm, and in non-vaccinated children a Mantoux reaction of
10mm, was considered positive. Other recent screenings in Sydney of Year 4 and
Kindergarten children have found TB infection prevalence rates of 16% and 13%
respectively".
Overseas data have shown that a 1% annual risk of infection in an unvaccinated
population represents an annual smear positive case rate of about 50 per 100,000
population•. Extrapolating from this, we estimate that the annual risk of infection in
NSW is between 0.04% and 0.05%.

ACTIVE TB NOTIFICATIONS BY AGE
NSW - 1991
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Aboriginality
Fig 5:

The active TB notification rate for Aborigines and Torres Strait Islanders of over 50
per 100,000 has been reported in Australia". Among Aboriginal communities in South
Australia the infection prevalence rate in the late 1980s was 16.8% with a range of
7.7%-30.8%9 •

country ol birth
Austr11.l111. !non AborJ
Australia [AborJ
UK and Ireland
Germany
Greece
Italy
Yugoslavia
Poland
Turkey
Ind ta
Cambodia
China
Vietnam
Phtltppines

In people known to be Aboriginal in NSW the annual notification rate of TB was 3.67.2 per 100,000 population in 1986-88. In 1991 only two cases of TB were reported in
Aboriginals.

NEW TUBERCULOSIS CASES BY PLACE OF BIRTH
NSW - 1970-1988
Fig 4:
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Country of birth and ethnicity
High rates of infection are found in ethnic groups and immigrants from high
prevalence TB countries". Most countries in Asia, Africa and Latin America are high
prevalence countries. In Australia only immigrants from the USA, Canada, New
Zealand and Scandinavia have incidence rates as low as, or lower, than the Australian
born population". Diseas.e rates in immigrants are highest in the first few years after
arrival. Ethnic groups tend to have a higher incidence of active disease especially in
10
the younger age groups (irrespective of country of birth) •

NEW MYCOBACTERIAL DISEASE NOTIFICATION
BY COUNTRY OF BIRTH - NSW 1986-1988
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In 1970, 80% of notified cases were born in Australia, but by 1988, this figure had
fallen to 26%. In 1991 31% of new cases were born in Australia. The age groups with
the highest proportion of new cases who were Australian born were the under five and
over 65 year age groups, being 75% and 50% respectively (Figure 6).
In NSW most cases of paediatric TB occur in children either born overseas or born in
Australia of Non-English Speaking Backgrounds (NESB). Of cases aged less than 15
years notified in 1991, 61% were born in Australia. However, of the Australian born
cases, 74% were from NESB. Of these 79% were from Asian backgrounds.
The high notification rate of TB in the age group 25-44 years in NSW is largely
accounted for by immigrants, with only 19% of cases in this age group being
Australian-born in 1991. In contrast, of those aged over 65 years 48% were Australian
born and a total of 60% were from English-speaking backgrounds.
For 1989-1991, among cases not born in Australia, 22% were notified within 12
months, 50% within five years and 79% within 15 years of arrival in Australia (Figure
7). As the proportion of cases declines with years after arrival, 'recent arrival' is a risk
factor for TB.

Data from census years show that notification rates of disease in NSW among people
born in Australia have fallen steadily since 1971, and among those born overseas only
since 1981 (Figure 4). From 1986 to 1988, among people born in Australia and not
recorded as Aboriginal, the notification rate of TB was 1.9-2.2 per 100,000 per year.
Notification rates of TB among people born in South East Asia exceeded 200 per
100,000 population. Rates of mycobacterial disease for selected countries of birth are
shown in Figure 5.

For 1990-1991 the Mantoux positivity rate in Indochinese screened by the NSW
refugee screening program was 46% in those who had been previously BCG vaccinated
and 40% in those who had not been previously BCG vaccinated15• The rates of chest
x-ray abnormalities detected by migrant/refugee screening in NSW in 1990 for
Vietnamese, Laotians, Kampucheans and Latin Americans were 116.6, 48.0, 95.2 and
105.0 per 100,000 population respectively16•
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TB CASES BORN IN AUSTRAL IA
AND OVERSEAS BY AGE
NSW 1991

number of new cases
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The risk of TB infection and pulmonary disease is higher in males than females ·' • In
1991 in NSW the male to female ratio for pulmonary disease was 1.5 : 1 and for
~apulmonary disease the ratio was 1 : Ll. The recent Mantoux screening survey of
police recruits in NSW estimated that, 7.7% of males and 2.9% of females have
7
tuberculous infection, a ratio of 2. 7 ; 1 •
Between 1963 and 1991 the proportion of notified cases who were male declined from
70% to 56%. Over the same period among Australian born people, the proportion of
cases who were male declined to a lesser degree, from 70% to 65%. In 1991 the
proportion of cases born overseas who were male was 53%. The more rapid decline in
disease among males compared with females is therefore largely an effect of
immigration.

50 ----------------------------------

0

Sex

Australia born

D

75+

The notification rate of disease in NSW males is twice that of females in the older age
groups. In 1991 the notification rate of active disease in those aged more than 65 years
was 20.1 per 100,000 for males and 10.1 for females (Figure 8).

J

ACTIVE TB I\OTIFICATICNS BY AGE
At\() SEX NSW - 1991
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OVERSEAS BORN ACTIVE TB CASES BY
YEARS SINCE ARRIVAL - NSW 1989-1991
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High infection rates are found in close contacts of active pulmonary TB cases. One
quarter of contacts of people with TB develop infection with those in close contact
being at greatest risk'°·". Up to 2% of contacts of newly discovered TB cases have
developed TB disease by their first examination13• The risk to contacts of
extrapulmonary cases is 1% 17 •
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Infected contacts are more likely to develop disease if infected by a culture positive
case with a positive direct sputum smear than a case with a negative smear. The risk
of infection depends largely on the density of Mycobacterium tuberculosis in droplets
expelled into the air by a person with TB and the time a susceptible person is exposed
to that air. The density of infected droplets in the air depends on the frequency of
coughing, the density of bacilli in the sputum and the volume of the air space.

Other medical risk factors

The risk of progression of infection to disease is high in immunosuppressed people.
Silicosis, malignant lymphomas, lung cancer, lymphosarcoma, reticulum cell sarcoma,
head and neck cancers, haemophilia, end stage renal failure and patients on
haemodialysis are associated with an increased risk of TB 10• Low body weight,
gastrectomy, diabetes, corticosteroid therapy, and HLA types All, B15 and DR2 have
In NSW in 1991 3.6% of notified active cases were known contacts of other reported also been implicated'". Smokers, particularly those with chronic lung disease, are at
increased risk".
cases.

Long term residential facilities
Human Immunodeficiency Virus (HIV) infection
In US prisons TB is a major health problem and is increasing. The incidence among
The increased incidence of TB overseas, notably in the US in recent years, is partly New York State prison inmates increased from 15.4 per 100,000 in 1976-1978 to 105.5
due to an excess of active disease in those with TB-HIV coinfection and partly due to per 100,000 in 1986, 56% of whom were infected with HIV'". Eleven outbreaks in US
increasing poverty and homelessness.
prisons were reported in the period 1985-198818• In the US the incidence of TB in
nursing home residents is higher than among elderly people living in the community
Although Mycobacterium avium complex is the commonest mycobacterial species (39.2 per 100,000 versus 21.5 per 100,000)19•
isolated from people with acquired immunodeficiency syndrome (AIDS), infection of
people with AIDS with Mycobacterium tuberculosis has the potential for more serious In NSW for the period 1989-1991, there were five notifications of active disease in
health consequences in the general community, because of its capacity to infect people people identifiable as being resident in nursing homes, three notifications from
with normal immune systems. TB-HIV coinfection is characterised by more widespread psychiatric institutions and one notification from gaol.
TB disease with unusual clinical features which makes diagnosis difficult.
survey to estimate the prevalence of infection in new prisoners at Tamworth gaol is
In NSW at present the notification rate of TB-HIV coinfection is low. In 1991 only ten · currently underway.
cases of TB (2.5% of all NSW notifications) were recorded in HIV positive people
(Figure 9).
Homelessness

Fig 9:

High prevalence rates of TB disease (1.6%-6.8%) and TB infection (18%-51%) have
been reported for homeless people overseas14• In NSW for the period 1989-1991 three
cases were notified from 'hostels for the homeless' and one case was recorded as being
of 'no fixed address'. Chest x-ray screening of homeless men attending 5 hostels in
astern Sydney during 1991 and 1992 showed that 15-25% of residents had results
. consistent with active or inactive TB.
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ccupation
n the US estimates of the annual incidence of infection in health care workers
HCWs) in recent years have varied between 1.5% and 10.3%20 • In South Australia
he prevalence of TB infection in HCWs under 45 years is 20%-30%9 • Research
aboratory staff handling infected material are considered at particular risk6 •
13

12

Occupation data are available for 951 of the 1044 notified cases (91%) between 1989 2 •
STRATEGIES
and 1991. Thirty seven cases (4%) were identifiable as HCWs. Of these 37 cases, 28
(76%) were born overseas. Of the nine Australian born cases, four were medical 2.1
GOALS AND TARGETS
practitioners (including one retired and two pathologists) and five were nurses
(including two retired and one a pathology nurse).
GOALS
Other 'occupational groups' considered at high risk are the unemployed and By 2001
pensioners6• The incidence of TB is strongly associated with socioeconomic status and
income".
•
To reduce the annual incidence of active TB disease to 2 per 100,000
population.

Old healed TB

By 1995

Those with old healed TB ·(abnormal chest x-rays with fibrotic lesions consistent with _ •
old healed TB) are at increased risk of active TB10•11 •

To reduce the annual incidence of smear positive TB to 2 per 100,000
population.

TARGETS

Geographical area
Disease containment
The notification rate of new TB disease is high in the Sydney metropolitan area and i
low in rural areas. The highest rates in 1991 were recorded for Central Sydney (15.4 By 1995:
per 100,000) and South West Sydney Area (12.7 per 100,000) (Figure 10).
•
To detect 95% of all smear positive cases.
Fig 10:

ACTIVE TB NOTIFICATIONS BY HEALTH
AREA/REGION
NSW 1991

ratell00,000

•

To ensure that 100% of smear positive cases are commenced on an appropriate
multidrug regimen within two weeks of diagnosis.

•

To ensure that 99% of smear positive cases have taken chemotherapy
continuously for six months after commencing treatment.
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By 2001:
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•

To detect 99% of all smear positive cases.

10

•

To cure 99% of all smear positive cases.

B

Case prevention

6
4

By 1995

2

•

To ensure that 95% of close contacts of smear positive cases are examined
within ten days of index case diagnosis.

•

To ensure that 90% of infected people commenced on chemoprophylaxis have
taken the drug(s) continuously for six months after commencing treatment.

O CSA ESA SSA SWS WSA WEN NSA CCA ILL HUN NCR NER OFR CWR SWR SER
Areal Region
II
Notes: CSA= Central Sydney; ESA"' East.em Sydney; SSA= Southern Sydney; SWS = South Western Sydney; WSA = Western Sydney; WEN =
Wentworth; NSA"' Northern Sydney; CCA = Central Coast; ILL= lllawarra; HUN = Hunter; NCR: North Coast; NER = New England &agion;
OFR"" Onma & Far West Region; CWR = Central West &gion; SWR = South West Region; SER= South East Region.

Surveillance

By 1995

•
14

To ensure that 100% of cases are notified.
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2.2

Chapters 3.2, 3.3, 3.5, 3.6 and 3.9 for guidelines.

IMPLEMENTATION INDICATORS

Disease containment
By 1993

Tuberculosis Advisory Committee (TBAC) to produce consensus
guidelines, including a Departmental circular, on TB treatment and case
follow up, which are endorsed by the Thoracic Society of Australia and
New Zealand (TSANZ) and National Health and Medical Research
Council (NHMRC). See Chemotherapy, Chapter 3.11.

By 1993

TBAC to produce consensus guidelines, (including a Departmental
circular), on chemoprophylaxis, including indications and recommended
first line drug regimens, which are endorsed by the TSANZ and
NHMRC. See Chemoprophylaxis, Chapter 3.10.

By 1993

Public Health Unit (PHU) Directors to ensure that:

•
By 1993

Epidemiology Branch (EHSEB) and Health Public Affairs (NSW Health ,
Department) to produce TB educational materials in a number of :
community languages - promoting early diagnosis and treatment, contact
follow up and access to TB services.

By 1993

NSW TB Coordinator to make annual projections of drug needs for the
State, based on surveillance of disease and drug resistance rates, and to
communicate these to suppliers via the Pharmaceutical Services Branch.

By 1993

NSW TB Coordinator to ensure that at least one teaching hospital is
established as a site for essential stocks - particularly drugs - and that
the site and stocks are regularly monitored.

By 1993

By 1994

By 1994

By 1994

Area TB Coordinators to establish local advisory groups, composed of •
representatives of high risk populations and agencies providing health
(including general practitioners), housing and welfare services to these
populations. These local groups will advise on priorities and the
development, implementation and evaluation of strategies appropriate to
high risk population groups, aimed at increasing awareness of TB,
facilitating access to care and improving compliance with treatment.

Improving liaison with Clinicians - Respiratory, Infectious
Disease, HIV/AIDS Clinicians and Paediatricians and
private practitioners. They should be made aware of the
notification criteria for TB which includes the presumptive
diagnosis. See Appendix 1 for case definitions of
tuberculosis.

•

Encouraging
telephone.

doctors

'

I

II

laboratories

to

notify

by

•

Delays in notification of more than five days are investigated and
action is taken to prevent similar delays in the future.

•

Chest Clinic Sisters (CCS) are phoned immediately on receipt of
notifications and copies of doctor and laboratory notifications are
forwarded by mail (pending networking of PHUs and Chest
Clinics).

By 1993

NSW and Area/ Regional TB Coordinators to ensure that the recording
and interpretation of Mantoux tests is standardised. See Mantoux
testing, Chapter 3.3.

Area/ NSW TB Coordinators to develop and evaluate specific strategies
for improving compliance with treatment regimens for each identified
high risk group. These strategies should be sensitive and responsive to
people's beliefs, cultures and environments and reflect an understanding By 1993
of the difficulties associated with behavioural change.

Area/ Regional TB Coordinators and PHU Directors to ensure that 90%
of close contacts of smear positive cases are examined within seven days
of diagnosis for child contacts and ten days for adult contacts.

By 1993

EHSEB to assess the risk of infection in 'high risk' health care workers,
by analysis of retrospective and/ or prospective data. See Health Care
Worker Screening and Protection, Chapter 3.4.

NSW TB Coordinator/ EHSEB to produce Departmental circulars of By 1993
guidelines for Mantoux testing, contact tracing, BCG vaccination, and
follow up of refugees and migrants on Health Undertakings (TBUs). See

TBAC/ EHSEB to review and update Health Department policy
regarding routine health care worker screening and BCG vaccination.
See Chapter 3.4.

ii

ii

and

Area TB Coordinators to ensure that the completeness of notifications is
routinely evaluated by review of pharmacy and bacteriology records
within all major hospitals for unnotified TB patients.

Case prevention
By 1993

•

By 1993
NSW TB Coordinator/ EHSEB to evaluate the acceptability and
accessibility of TB Services, from a sociocultural perspective, and to
implement and evaluate change as required.

EHSEB to evaluate and report on risk factors for treatment failure:
interrupted therapy, failure to complete therapy, relapse and chronicity.

95% of all confirmed and presumptive diagnoses of TB are
notified within five working days of diagnosis by :

16
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By 1993

EHSEB to assess the need for modification of TBU follow up and refugee By 1993
follow up protocols, by analysis of available data. See Chapters 3.5 and .

3.6.
By 1993

EHSEB to report on the risk of infection and for disease in the following
populations: new prisoners, the homeless and nursing home residents.
See Screening, Chapter 3.1 for discussion of the rationale for selecting
target groups for screening.

By 1994

EHSEB to report on the risk of infection and disease in intravenous drug
users and HIV seropositive people. See Chapter 3.1.

By 1994

EHSEB to report on the risk of infection and disease in Aboriginals.

By 1994

EHSEB to assess the potential value of periodic Mantoux screening of
children in 'high risk' areas, by cost effectiveness analysis.

By 1994

EHSEB to assess the value of refugee screening, by cost effectiveness ,
"'.i
analysis using available data.

By 1994

NSW TB Coordinator/ EHSEB to participate in national collaborative
study of overseas born TB cases notified in 1991, with the aim of
evaluating the effectiveness of follow up of migrants on TB Us.

By 1994

EHSEB to assess the need for modification of contact tracing guidelines,
by analysis of available data.

Area/ Regional TB Coordinators to report to the NSW TB Coordinator on
investigations of contacts of infectious cases within institutions (for
example, nursing homes, schools, hospitals, prisons, hostels for the
homeless, workplace) within one month of notification.

By 1993

Area/ Regional TB Coordinators to report annually to the NSW TB
Coordinator on infection rates for all screened population groups.

By 1993

NSW TB Coordinator/ EHSEB to undertake validation studies of TB
notifications every two years, by review of selected records systems (for
example laboratory reports, pharmacy reports, death certificates).

By 1994

EHSEB to write a program which translates computerised information
from ICPMR mycobacteriology laboratory into a form compatible with
the IDSS.

By 1995

At least one Health Area with a high incidence of TB to undertake
periodic (three-five yearly) surveys of the prevalence of tuberculous
infection in children of various ages.

By 1995

All Area Health Services to provide access for Chest Clinics to the
expanded version of IDSS, by computer networking of Chest Clinics and
PHUs. Chest Clinics to be responsible for using the network IDSS to
update notification details, monitor infection rates in high risk
populations and for program evaluation.

Program evaluation
Surveillance
By 1993

EHSEB to expand the NSW Infectious Diseases Surveillance System
(IDSS) database to include additional data related to TB cases, eg drug
sensitivities, source of discovery (see Appendix 2).

By 1993

EHSEB to expand the NSW IDSS database to include data related to
infection:

By 1993
I'

•

contact follow up - eg new infections detected (contacts relational
file)

•

other screening - eg. infections detected in health care workers
and other high risk populations (screening module).

By 1993

TBAC to agree upon a core set of program evaluation indicators for
Areas/Regions and the State. See Appendix 3 for proposed set of program
evaluation indicators.

By 1993

EHSEB to expand the NSW IDSS database to include additional case
follow up details, to facilitate program evaluation and patient
management, eg related to drugs prescribed, duration and interruption
of chemotherapy, and bacteriologic conversion (TB case module). These
additional details should directly relate to the core set of program
evaluation indicators (see Appendix 2).

EHSEB to link the NSW IDSS database with Australian Bureau of
Statistics mortality data for estimation of prevalence of active and By 1993
inactive TB disease at death and hence the case detection ratio.

I,
By 1993

i'

NSW TB Coordinator/ EHSEB to report annually at the State level on
indicators of TB disease and infection: rates of TB disease (and smear
positive disease), hospitalisation and mortality; reactivation; HIV-TB coinfection; drug resistance; TB meningitis (children aged less than five); By 1994
and infection rates for all screened population groups. See Appendix 3
for proposed set of disease and infection surveillance indicators.

The expanded IDSS should include a programmed reporting facility
which generates program evaluation indicators for specified periods of
case notifications by cohort analysis.
Area/ Regional TB Coordinators to report quarterly to the NSW TB
Coordinator on program evaluation indicators for case management and
follow up related to: delay in diagnosis and notification; initiation of
appropriate drug regimen; drug continuity and completion; treatment
failure; cure; case fatality (see Appendix 3).
EHSEB to expand the NSW IDSS database to include information from
screening, to facilitate program evaluation and patient management:

!

I!
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By 1994

By 1994

•

contact tracing details eg time until follow up, new infections
detected (contacts relational file/ screening module).

•

'satellite' Clinics (run by CCS at locations remote from their base
Clinic) are rationalised,

•

other screening data eg drugs prescribed, duration
interruption of chemoprophylaxis (screening module).

•

in these small rural localities at least one nominated registered
nurse (hospital and/ or community based) is trained in and
performs all basic TB related duties (Mantoux testing; BCG
vaccination; supervision of anti-TB chemotherapy; routine follow
up of contacts, inactive cases and migrants on TBUs), and

•

the routine follow up of inactive cases, migrants on TBUs and
contacts who live remote from a Regional Chest Clinic is
coordinated and supervised by the nearest CCS.

and

Area/ Regional TB Coordinators to report annually to the NSW TB
Coordinator on program evaluation indicators for screening related to:
delay in examination of contacts; location of contacts; infection rates for
all screened populations; initiation of chemoprophylaxis; drug continuity
and completion (see Appendix 3).
NSW TB Coordinator to report annually to EHSEB on program
evaluation indicators for case management/ follow up and screening.
. By 1993

NSW and Area/ Regional TB Coordinators to develop inservice training
modules for health care workers (and workers in long term care
facilities) about the risks of TB transmission, signs and symptoms,
methods of diagnosis, procedures for minimising risk and accessing TB
Services.

By 1993

NSW TB Coordinator/ EHSEB to develop program evaluation training
modules and guidelines for Area/ Regional TB Coordinators.

Services
By 1993

By 1993

By 1993

NSW TB Coordinator/ PHU ·Directors to nominate TB coordinators for
each Area/ Region, who will be responsible for:

•

program evaluation and quality assurance, and

•

ensuring and monitoring the implementation of Statewide policies
and guidelines, recommendations from the NSW Review of TB By 1993
Services 1992 and other responsibilities outlined in this
document.

NSW TB Coordinator/ EHSEB to incorporate updated Statewide
guidelines and policies related to TB control into a standard 'Policies and
Procedures Manual', which is distributed to NSW Chest Clinics, PHUs
and hospitals, as well as Regional Community Health Services.
Area/ Regional Health Services should aim to have

•
•

Chest Clinics staffed with Physicians with special training in TB,
and

y 1994

NSW TB Coordinator to annually update the NSW TB 'Policies and
Procedures Manual'.

y 1994

Area TB Coordinators/ Area Health Services to ensure that:

•

staff who provide TB Services receive appropriate training to
facilitate effective communication with high risk groups, and

•

staff are culturally sensitive to the populations being served.

in rural areas where Physicians with training in TB are no
available, all active cases to have treatment initiated and cease
by and be discharged from medical care by such a Physician fro
the most accessible Chest Clinic.

By 1993

Area/ Regional Health Services to ensure that all Area hospitals, and
major Regional hospitals or Community Health Services, have at leas
one registered nurse trained in routine Mantoux testing and BC
vaccination of staff and patients.

By 1993

Area/ Regional Health Services to ensure that:

)i

Area/Regional TB Coordinators/Health Services to ensure that
appropriate mechanisms are in place within hospitals to facilitate
effective liaison and coordination between Infectious Diseases, HIV/AIDS
and Chest Clinic medical and nursing staff.

I
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3.

POLICIES

8.1

SCREENING · TARGET GROUPS

•
•

•

•
•

•

Due to the low yield, mass population screening is not justifiable except for
subgroups with high rates of infection. The rationale is to identify those who
would benefit from chemoprophylaxis (or chemotherapy). Screening, by Mantoux
testing, is generally recommended where the rate of infection is greater than
1%'.

Screening chest x-rays are rarely justified, except when:
a)

The objective is to identify those with current pulmonary disease
and the administration of chemoprophylaxis to infected people is
not possible". Those in hostels for the homeless are suitable for
screening by chest x-rays (and possibly sputum smears).

b)

There is a high probability of false negative Mantoux reactions, eg
in immunosuppressed people. Therefore, a high index of clinical
suspicion of pulmonary and extrapulmonary disease should be
maintained and appropriate investigations performed for people
with clinical AIDS or other HIV related disease, regardless of the
results of Mantoux testing''.

Routine screening:

•
•

..
(ii)

Prison inmates on admission - Mantoux screening survey
Nursing home residents on admission - chest x-ray screening
survey
Injecting drug users - Mantoux screening survey ·

Periodic surveys (frequency depending on the estimated risk)

•
•

'Medium risk' HCWs - Baseline screening surveys and/ or
collation and analysis of available data (See Chapter 3.4)
Aborigines - Mantoux screening survey

Routine screening
•
•
•
•

•

!I
'

(i)

In NSW the following groups should be screened by Mantoux tests (unless
otherwise indicated) on a routine or periodic basis:
(i)

I

To identify other high risk groups in NSW, baseline data should be obtained to
estimate risk and hence evaluate the need for screening on a routine or periodic
basis. The risk should be estimated either by baseline screening surveys or
collation and analysis of available data, as indicated:

The predictive value of Mantoux tests is low in populations with a low ,
prevalence of infection. This means that in low risk populations, eg the general i
population or distant contacts (eg workmates) of cases of low infectiousness, a
large proportion ofMantoux positive people will not be truly infected.

AB rates of disease decrease, the value of continued screening should be
regularly assessed.

'High risk' HCWs - 12 to 24 monthly Mantoux tests (depending
upon estimated risk).

(ii)

Close contacts of people known or suspected to have clinical TB
People with medical risk factors for TB
People with HIV infection
Health care workers/ students at the commencement o
employment
Immigrants (migrants and refugees) from high prevalenc
countries

Periodic screening
•

Residents of hostels for the homeless - six monthly chest x-ra
screening

22
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8.2

CONTACT TRACING AND FOLLOW UP

A.

Aims

(1)

'Medium'

The aims of contact tracing are:
1.

Categorise the case according to the likely degree of infectiousness
direct sputum smear positive and/ or chest x-ray cavitation

=

sputum culture positive and direct smear negative, no
chest x-ray cavitation

=

sputum culture and direct smear negative

=

extrapulmonary TB (and atypical mycobacterium)

to identify those infected by the index case, and/ or

2.

to identify a source of infection for the index case.
'Negligible'

B.

=

Notification of cases to Chest Clinic staff
(As culture and identification results are not routinely available for some

weeks, initially cases of 'medium' and 'low' infectiousness will not be
distinguishable and atypical mycobacteria will not have been identified.)

PHUs should immediately report case notifications to the nearest Chest Clinic,
by phone initially, followed up by sending copies of notifications. ('Notifications'
include all doctor notifications of TB and laboratory notifications of
mycobacterial infection.)

Timing and extent of contact tracing investigations

Obtain a list of contacts and categorise the contacts according to their
estimated risk

The estimated risk of transmission should guide the priority, rapidity and
thoroughness of contact investigation.

A list of close contacts, including names and addresses, should be compiled first.
Contacts should be categorised into:

The following steps, summarised in the box, should be undertaken. These steps
are described in full on the following two pages.

'High risk' group = frequent, prolonged and close contact within last three
months (or as far back as a clear history of active TB disease). This group
includes:

(2)

c.

•

all people living in the same dwelling

1.

Categorise the case according to the likely degree of
infectiousness.

•

relatives and friends who have frequent, prolonged and close
contact

2.

Obtain a list of contacts and categorise the contacts according
to their estimated risks.

•

any others who have spent 8 hours or more with the case in a
closed environment.

3.

Examine all 'high risk' contacts of pulmonary TB cases first.

4.

Consider examination of 'medium risk' (followed by 'low risk')
contacts of pulmonary TB cases.

'Medium risk' group - frequent but less intense contact. This group includes:

5.

!

•

other close relatives, friends, schoolmates and work colleagues eg
neighbours, relatives who frequently visit the case's home.

Consult with the Medical Officer of Health and NSW TB
Coordinator, if:

•

the case works in a hospital, school, day care or long
term care facility,

•

screening is indicated for more than 25 contacts, or

•

if in doubt about the priority/ extent of contact
screening required, for any reason.

!I

The 'Low risk' group includes other contacts at school (especially Primary
Schools) or in the workplace or in clubs. However, obtaining details of'low risk'
contacts is not necessary initially and need only be pursued if there is evidence
of transmission in the 'high risk' and 'medium risk' groups.

i'
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(3)

Examine all 'high risk' contacts of all pulmonary TB cases first

D.

•

•

'High risk' contacts of highly infectious cases should be exainined within
seven days of notification for child contacts and 10 days for adult
contacts.

•

'High risk' contacts of cases of 'medium'/ 'low' infectiousness should be
examined within 10 days of notification (or before the case is discharged
from hospital).

•

Contacts of cases with 'negligible' infectiousness need not be examined.
(Contacts of cases of pulmonary atypical disease should have been
examined once, however, before identification results are available.)

Procedures
Contacts who are Mantoux negative throughout follow up:
First visit
i)
ii)

Mantoux test
chest x-ray - unless aged less than 15 years
- chest x-ray to be reviewed by physician

48-72 hours later
iii)

read Mantoux reaction

Second visit - 12 weeks after 1st visit
(4)

Consider examination of 'medium risk' (followed by 'low risk') contacts
of pulmonary TB cases.

•
•

i)

48-72 hours later

Only if there is evidence of transmission in the 'high risk' .
contacts group, should screening progress to the 'medium risk' 1l
group.

ii)

i)

'Evidence of transmission' means recent Mantoux conversion and no other
identifiable source of infection.

Consult with the Medical Officer of Health in your Area/ Region and
the NSW Tuberculosis Coordinator if:

ii)

•

Contacts who are Mantoux positive at any visit must have a chest x-ray
taken, and be referred to a physician for assessment for chemoprophylaxis (or
chemotherapy). The alternative is annual chest x-rays for up to two years.

•

Child contacts aged less than five years who are Mantoux positive
should be referred to a physician for assessment for chemoprophylaxis (or
chemotherapy).

the case works in a hospital, school, day care facility or long •
term care facility (nursing home, hostel or prison), or

Ii
ii,,

•

screening is required for more than 25 contacts, or

1!

•

in doubt about the priority/ extent of contact tracing require
for any reason.

!'

,j

'High risk' child contacts aged less than five years who are Mantoux
negative on the first visit should be referred to a physician and be given
chemoprophylaxis until the 12 week Mantoux test is shown to be negative,
unless contraindicated.

•

Child contacts aged less than 16 years who are Mantoux negative and
~av~ ~ontinuous exposure to an active case and a) cannot be placed on
isom~z1d orb) are exposed to a case with organisms resistant to both isoniazid
and rifampicin, should be considered for BCG vaccination prophylaxis.

•

These procedures will be reviewed penr;ling results from a contac{ tracing
survey which is currently being conducted.

I,!
11

read Mantoux reaction

There should be no further routine follow up.

•

11

Mantoux test

48-72 hours later

If ten or more of the closest contacts have been tested and all are Mantoux
negative, testing of more remote contacts is usually unnecessary.

(5)

read Mantoux reaction

Third visit - 12 months after 1st visit

Only if there is evidence of transmission in the 'medium risk'
group, should screening progress to the 'low risk' group.

If less than ten contacts have been tested, and all are Mantoux negative, careful
consideration should be given to the theoretical risk of infection before stopping
the contact investigation.

Mantoux test
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Figure 11 : Management of Mantoux Negative Contacts
Figure 12 : Management of Mantoux Positive Contacts
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No follow-up
required
unless
symptoms
develop

Interpreting the test
3.3

MANTOUX TEST

A.

Procedure

•

Reactions are considered positive if there is induration of at least:
(i) 5 mm:

•

Client position - Still, seated.

•

Site - Upper third and middle part of anterior aspect of left forearm for
human PPD (unless contraindicated eg large tattoo or birthmark) away
from the veins and if possible free from hairs, scars and tattoos. Children
with positive Mantoux reactions should be tested with avium PPD in
their right forearm.

'

'

I

for recent close contacts of infectious TB cases, and
for people with chest x-rays consistent with healed TB.

•

B.

•

Equipment - 1ml tuberculin syringe with a 26 gauge needle

•

Dose - 0.1ml of PPD (Purified Protein Derivative) tuberculin 10IU

•

Method - Intradermal injection only

•

Character - A "bleb" of approximately 7-Smm in diameter forms
immediately after the injection.

(ii) 10mm:

f
I

Skin preparation - Swab the area with an alcohol swab. The skin must
be dry before injection.

i

When? - 48-72 hours after the injection

•

What? - Induration NOT erythema

•

How? - "BALL POINT TECHNIQUE" is more accurate than the
traditional finger tip technique of measuring induration.
(1)

Draw a line with a "medium" ball point pen from a point 2-3cm
away from the margin of the skin test reaction towards its centre.
Maintain skin tension by exerting slight traction opposite to the
direction of the pen movement.
Exert moderate pressure against the skin and move the pen
slowly.

(2)

Lift the pen when the ball point reaches the margin of the
indurated area and there is definite resistance to further ·
movement.

(3)

Repeat the procedure from the opposite side of the reaction.

(4)

Measure the distance between opposing lines by a calliper or
ruler. Record in millimetres and do NOT round your reading to
the closest 5mm.
30
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for others (including those who have had BCG vaccination).

•

People with positive reactions should be referred for medical assessment.

•

Positive reactions usually mean that the person has been infected
with M. tuberculosis. Only 5-10% of people who have been infected are at
risk of developing disease at some time in their lives.

ifii
1,
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1

•

Reading the reaction
•

for people with HIV infection or risk factors for HIV
infection with unknown HIV status

i

II

'False positive' reactions mean that the person has a positive reaction
but has not been infected M. tuberculosis. This can occur because of:

•

exposure to other types of mycobacterium which do not usually
cause disease, or

•

previous BCG vaccination, especially recent .

Management would depend upon the risk of infection and should be
assessed individually.

•

'False negative' reactions mean that the person has a negative
reaction but has been infected with M. tuberculosis. This can occur:

•
•

before hypersensitivity develops ie during the "incubation period"
(usually 4-12 weeks)
with faulty technique eg poor or expired tuberculin, leaking
syringe, injection too deep

,i

I
!1

Ill
I,

i

•

during advanced or terminal stages of TB

•

with immunosuppression eg HIV infection

•

during corticosteroid,
treatment

•

with severe malnutrition, dehydration or inanition

•

in the elderly, particularly with chronic illness and poor nutrition

•

after an attack of pertussis (whooping cough) or measles

31

anti-histamine

111

'j!

or

anti-inflammatory

I

3.4

HEALTH CARE WORKER SCREENING AND PROTECTION

•

•

A high index of suspicion should be maintained to allow early identification and
treatment of infectious patients. Effective multidrug therapy should be initiated
promptly based on clinical and drug surveillance data.

All HCWs should be evaluated according to routine contact tracing procedures if
they are exposed to a potentially infectious TB patient for whom adequate
infection control procedures had not been taken .

•

Documentation of the results of employment related Mantoux tests and chest xrays must be maintained by the health care institutions.

•

•

Infection control measures should follow established gnidelines for AFB
isolation precautions; cleaning, disinfecting and sterilising; ensuring adequate
ventilation; and special precautions during cough inducing and aerosol
generating procedures.

PROPOSED CATEGORIES OF RISK FOR HEALTH CARE WORKERS
1.

Policy for TB control among hospital staff should be uniform throughout NSW
because movement of staff is common. Health care workers (HCWs) should
carry a personal record of BCG vaccination and results of employment related
screening from one employment to another.

'High' risk category

i

,,1
1,

•

All staff working within respiratory clinics and designated chest clinics

•

Staff in bronchoscopy theatres

'I
!,'i!I'
I

'

1

•

•
•

All medical, nursing, pathology, radiology and paramedical hospital staff
should:

•

Medical, nursing staff, radiographers, physiotherapists and students who
regularly work with TB or HIV positive patients

•

receive a Mantoux test on employment unless there is documentation of
a positive Mantoux test, adequate treatment for disease or infection, or a
negative Mantoux test within the previous three months, and

•

Laboratory staff working with tuberculous material, for example,
mycobacteria laboratory, bacteriology, cytology staff

•

Mortuary staff

•

be offered BCG vaccination if Mantoux negative.

HCWs should not commence work in a high risk area without prior adequate
screening.

j

,11

2.

I:

1I'

"I

Whether and how often screening (Mantoux tests or chest x-rays for Mantoux
positive workers) is undertaken during employment should depend on the
estimated risk of infection (ie Mantoux conversion rates in cohorts of
unvaccinated HCWs).

Other medical and nursing staff, physiotherapists, radiographers,
paramedical staff and students involved in direct patient care not
included in 'high' risk category

•

Ambulance personnel

•

•

Non clinical staff who are regularly in close contact with patients, for
example, wardsmen

HCWs should be classified into 'high', 'medium' and 'low' risk groups.
Categorisation of potential risk should depend on a) occupational group,
b) risk in community served by health care facility, and c) area worked
in health care facility.

3.

•

•
•

'Medium' risk category

•

•

'High risk' Mantoux negative HCWs should be periodically screened by
Mantoux tests during employment. The frequency of screening (eg
annually or biannually) should depend on the estimated risk of infection.
'Medium risk' Mantoux negative HCWs should also be periodically
screened by Mantoux tests during employment, unless the risk of
infection is shown to be less than 1% per annum.
'Low risk' HCWs should not be routinely screened during employment.

'Low' risk category
•

Note:

Staff who are not routinely exposed to patients or their clinical
specimens, for example, kitchen staff, administration and clerical staff

Occupational risk is not as much a concern in paediatric hospitals as in adult hospitals because
children rarely cough sufficiently or have sufficient cavitatory disease to generate viable organisms.
TB incidence in paediatric hospital HCWs probably reflects the incidence in the general population,
rather than an occupational risk2 2 2 3. More of a concern is transmission from HCW with
undiagnosed tuberculosis to patients .

Data on skin test conversions in HCWs should be periodically reviewed so that
infection risk can be estimated and the frequency of retesting should be altered
accordingly.

32
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3.5

•

REFUGEE SCREENING AND FOLLOW UP"'

3,6

HEALTH UNDERTAKINGS (TBU) FOLLOW UP

Refugees who are Mantoux negative throughout follow up :

(A)

Migrants who have abnormal premigration chest x-rays (which may or may not
be tuberculous in origin) and/ or have had TB treatment may be permitted
entry to Australia if they agree to sign a Health Undertaking (TBU) to adhere
to the following conditions:

First visit
Mantoux test
chest x-ray - unless aged Jess than 15 years; chest x-ray to be reviewed

i)

•

report to the state/territory contact authority (in NSW, the TB
coordinator based at Lidcombe Hospital) initially by telephone within
one (or if advised, four) weeks of arrival

48-72 hours later

•

place themselves under the authority's professional supervision

iii)

•

agree to undergo any further tests (eg, Mantoux test, chest x-ray and
medical examinations) as necessary

•

agree to undergo any course of treatment which the authority directs

•

inform the authority each time they change address in Australia
throughout the period during which the authority is monitoring the
migrants

•

inform the authority whenever they are about to leave Australia and
report to the authority on return

•

inform the Australian visa office if, before departure, the proposed
address in Australia or the travel times change

ii)

by physician

'i:'

read Mantoux reaction

Second visit - 6 months
i)

Mantoux test

48-72 hours later
ii)

read Mantoux reaction

Third visit - 18 months
i)

Mantoux test

48-72 hours later

(BJ

Migrants are referred by the NSW TB Coordinator to their nearest Chest Clinic.

ii)

(C)

Chest Clinic appointments should be made:

read Mantoux reaction

There should be no further routine follow up. Refugees should be advised to
seek medical advice if symptoms develop.

•

•

Refugees who are Mantoux positive at any screen must have a chest x-ray,
and see a physician for assessment for chemoprophylaxis (or chemotherapy).
The alternative is chest x-ray follow up for up to two years.
Refugees with chest x-ray abnormalities
immediately.

should see a

physician

(D)

•

immediately - if a) migrants have had TB treatment, or b) their premigration chest x-ray abnormalities are suspicious of active TB disease,
and

•

within six months after the pre migration chest x-ray - for others .

Routine follow up - if had previous TB treatment
First Visit
i)

ii)
iii)

chest x-ray - to be reviewed by physician
sputum (3) for AFBs - as indicated
see physician

Second Visit - 6 months
i)
ii)

34

chest x-ray - to be reviewed by physician
see physician if any changes

35

Third Visit - 18 months
chest x-ray - to be reviewed by physician
see physician if any changes

i)
ii)

3.7

HIV/AIDS AND TUBERCULOSIS

•

The changes in cell mediated immunity, that occur in HIV related disease,
facilitate the development of TB disease. The defect in the hypersensitivity
component of immunity also diminishes host tissue responses, and in the late
stages of HIV related disease, results in more easily disseminated disease and a
different clinical picture25•

•

A high index of clinical suspicion of pulmonary and extrapulmonary TB in
patients with HN infection should be maintained and appropriate
investigations, such as Mantoux testing, should be performed.

•

HIV testing should be offered to patients with active TB, if they have a high
risk profile for HN infection, if they have a low risk profile for TB and /or if
they have extrapulmonary TB. Risk factors for HIV infection include history of
homosexual contact, intravenous drug use, or migration from countries with
high prevalence of HIV infection, for example South East Asia and Africa6 25 •

•

All HIV seropositive people with a Mantoux reaction > 5mm should have
chemoprophylaxis, unless medically contraindicated. Recommended duration is
at least 12 months with good supervision and follow up should continue
indefinitely2 1•

•

All HIV seropositive people with clinical AIDS or other HIV related disease
should have a chest x-ray and be examined for extrapulmonary TB, regardless
of the results of Mantoux testing.

•

Active TB in HIV seropositive (and other immunocompromised} people should
be treated with conventional medications but for three months longer than for
other patients, or for a minimum of six months after sputum cultures become
negative. Follow up of HIV/AIDS patients should continue indefinitely•.

•

BCG is contraindicated in immunosuppressed patients• .

•

Infection control measures for TB should be in place when investigating
patients with HIV infection.

•

Care should be taken with TB patients in health care settings, in particular
HIV-TB coinfected people who are direct smear positive, to avoid their contact
with immunosuppressed people (including Health Care Workers). Investigations
and treatments which induce coughing, thereby spreading infected droplets,
should be avoided.

•

Mycobacterium isolated from HIV seropositive patients should not be assumed
to be atypical mycobacterium, for example mycabacterial avium, until
confirmation.

. ·ts annually for up to two more years
Further VJ.S1 chest x-ray - to be reviewed by physician
see physician if any changes

i)

ii)

(E)

. not h ad p revious treat:inent
Routine follow up . if
First visit
of Mantolll negativity or no
Mantoux test - if documentation
documentation of Mantoux statusd
d/ or if Mantoux positive and/
chest x-ray - if aged 15 years an . o_ver .anhest x-ray to be reviewed by
. t·10n chest x-ray susp1c10us, c
or prenugra
physician
.
sputum (3) for AFBs - as indicated

i)
ii)

iii)

i

48-72 hours later:
iv)

read Mantoux reaction

·t· e Mantoux reactions should be
l h t x-rays or pos1 iv
Migrants with abnorma c es_
df
h moprophylaxis or chemotherapy.
seen by a physician to be cons1dere or c e
.
mi ation chest x-rays and no other ri_sk factors (eg
Migrants with clear post- gr
) h uld be discharged immediately.
Mantoux positive and recent contact s o
Second visit - 12 months
i)
ii)

d over· chest x-ray to be reviewed by
chest x-ray - if aged 15 years an
,
physician
see physician if any changes
b
alities and no other risk factors
ts with stable minor chest x-ray a norm
be discharged after 12 months follow up.

s::

M.

Third visit • 24 months
i)
ii)

'f aged 15 years and over; chest x-ray to be reviewed by
chest x-ray - 1
.
physician
see physician if any changes

Migrants with stable chest x-ray abnorm

alities should be discharged after

months follow up.

.
TBUs should be advised to seek medical attent1
On discharge, migrants on Ch t Clinic if they develop any symptoms.
immediately at the nearest
es
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3.8

D.

TUBERCULOSIS IN CHIWREN AND ADOLESCENTS""

Tuberculosis (TB) in children and adolescents differs markedly from TB in adults with
regard to the following aspects.

A.

Risk of disease following primary infection

The lifetime risk of post-primary tuberculosis disease in adults following primary
27
infection is in the range of 5-10%. However, this risk is much greater in children :

•
•
•
B.

year - 50%
<1
years - 25%
1-5
11-15 years - 15% (females>males)

E.

TB in children is "primary" TB, a disease which is predominantly one of delayed
hypersensitivity with few organisms and variable immune response. Childhood TB is
rarely contagious except in older adolescents with cavitatory disease or laryngeal TB.
The reasons are:

C.

Due to the incre:35~d risk of TB disease in children, especially under the age of 5 years,
chemopro~hy~IUO~ 18. more co~only recommended than in adults. Chemoprophylaxis,
usually with 1soruazid alone, 1s recommended for all children and adolescents who are
Mantoux positive but have no clinical or radiological evidence of TB. Jn the < 5 year
age group, chemoprophylaxis is indicated if very high risk, irrespective of Mantoux
status, until th~ ~epea~ Mantoux test is shown to be negative (three months).
Chemo~rophyl1UOs m children, especially under the age of 5 years, should ideally be
supervised.
In contrast to adults, the incidence of liver toxicity from isoniazid in clilldren is
extremely low. Liver function is evaluated only when clinically indicated and routine
monitoring of liver function is not recommended.·
'

Infectivity

•
•
•

Chemoprophy1axis

children with TB disease usually have a small tubercle load,
children very rarely have cavitating disease, and
children usually swallow their sputum, and have a far less effective
cough than adults.

Treatment

It is recommended that children are treated with daily therapy with at least three
drugs (usually isoniazid, rifampicin and pyrazinamide) for the first two months.
Generally 2 drugs (isoniazid and rifampicin) are then used for a further 4 months and
can be given daily or three times a week. Short course chemotherapy (6 months) has
been shown to be effective in children, but there are insufficient data to recommend it
for CNS, bone or joint TB infections. All treatment regimes in children should be fully
supervised.

Diagnosis

A Mantoux reaction is considered positive28 in a child if:

•
•
•

2: 5 mm . when child is at high risk of infection. ·
;;,: 10 mm • when at moderate risk of infection or BCG 2:: 5 years prior.
z 15 mm • when at low risk of infection or BCG within 5 years .

Risk Categories
filGHRISK

MODERATE RISK

LOW RISK

Contacts of infectious
cases

Ethnic origin from high
prevalence populations

No risk factors

HIV infected or other
immunosuppressed (including
steroids)

Locally identified high risk
populations

Abnormal chest x-ray

Children < 5 years

38
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3.9

c.

BCG VACCINATION

BCG (Bacille-Calmette-Guerin) vaccine contains a live attenuated st~ .of
Mycobacterium bovis - the mycobacterium has lost its vii:u1ence b~t retams _its
antigenic property. BCG can produce immunity, overseas tnals sho~g p~otect~on
varying from 0-75%, but rarely produces disease. In contrast, natural infection with
virulent M. tuberculosis produces immunity, and causes disease in 5-10% of people.

A.

Indications

BCG vaccination should be offered to Mantoux negative people who are:

•

Mantoux reaction - Must be < 5mm. For contacts, must be < 5mm at
the 12 week follow up. For neonates (less than one month old) BCG
vaccination is done without perfonning a Mantoux test.

•

Client position - Still, seated with head turned in the opposite direction
of the injection site

•

Site - Middle part of the left deltoid area

•

Skin preparation - Swab the skin with acetone swab and make sure
it's dry before vaccination.

•

belong to groups with new infection rates more than 1% per year,

•

Equipment - 1ml tuberculin syringe with a 26 gauge needle

•

have continuous exposure to cases with active disease and cannot
be placed on isoniazid therapy, or

•

Dosage - 0.1ml (0.075ml for neonates)

•

Method - Intradermal injection ONLY ie just under the skin surface
(NOT SUBCUTANEOUS)

•

Character

have continuous exposure to cases with organisms resistant to
isoniazid and rifampicin

•
•

B.

Procedure

children aged less than 16 years who:

•

neonates from ethnic groups with a high prevalence of TB or with a
family history of TB

•

medical, nursing, pathology, radiology and paramedical hospital staff

i)
ii)
iii)
iv)
v)
vi)

•

Contraindications

age > 35 years

•

pregnancy

immediate - "bleb" of about 8mm diameter forms
30 minutes later - "bleb" disappears
2-3 weeks later - papule of 2-4mm forms
2-4 weeks later - pustule forms
2-3 months later - pustule ruptures and small ulcer forms
within 3 months - scar of about 5-7mm diameter forms

I

Ulcer care
i)

Relative:
•

'1

!

children and adults who are travelling overseas to live in a high
prevalence country for a prolonged period (12 months or more)

•

•

I'.

ii)
iii)

iv)

Keep it open - ie. no dressings or topical treatments.
Avoid bumps and scratclies.
Continue normal activities - eg. swimming, sports.
Apply a sterile gauze loosely - if necessary, for cosmetic purposes.
Do not apply strapping near the ulcer.

; i
I
!

•

•

Absolute:

•

primary or secondary immunosuppression, ~eluding people: wi~h
HIV infection or high risk for HIV infection where status 1s
unknown; receiving oral corticosteroids, immunosuppressive drugs
or irradiation

•

malignancies involving bone marrow or lymphoid systems

•

septic skin conditions

•

Mantoux reaction > 5mm

Follow up
Repeat Mantoux tests are not indicated if a good BCG scar has formed .

i

!1
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3.10

CHEMOPROPHYLAXIS

•

Unless specifically contraindicated, chemoprophylaxis should be considered for
all high risk Mantoux positive people, such as :
•

contacts of people with TB

•

recent Mantoux converters (within two years)

•

people with medical risk factors for TB

•

HIV infected people

CHEMOTHERAPY

!

Chemotherapeutic regimens for tuberculosis should be chosen in accordance
with the National Health and Medical Research Council (NHMRC)
guidelines6•

•

A high index of suspicion should be maintained to identify cases rapidly. This is
particularly the case for patient populations who commonly present atypically,
for example, the elderly and HIV patients.

•

Effective multidrug anti-TB therapy should be initiated promptly based on
clinical (high index of suspicion or confirmation) and drug resistance
surveillance data.

•

If drug resistance is suspected, cases should be treated as drug resistant until
proven otherwise. Drug resistance should be suspected with a history of
previous chemotherapy, especially if inadequately supervised or documented, or
place of birth in Asia, Africa or Latin America.

Chemoprophylaxis should be offered to all Mantoux negative children under five
years of age who are close contacts of high risk (direct smear positive) people
with TB. Prophylaxis should continue until a repeat test in 12 weeks (after
contact is broken) is shown also to be negative.

•

Drug regimens of at least six months duration are recommended for both smear
negative and smear positive patients. In any case therapy must be long enough
to fulfil the requirements of the given regimen. Pyrazinamide must be included
in the first two months of any six month regimen6.

•

Chemoprophylaxis should be for a minimum of six months. Six month regimens
are preferable to maximise compliance and minimise costs. Exceptions are those
with HIV infection or an abnormal chest x-ray consistent with old inactive TB
who should be treated for at least 12 months.

•

Chemotherapy should be fully supervised, with a three times weekly regimen,
for all pulmonary and extrapulmonary cases. Full supervision requires the
actual observation of drug ingestion and a written record of drug administration
(patient and clinic held).

•

Direct supervision with three times weekly short regimens is indicated for
children aged less than five years of age and others at high risk of developing
TB.

•

The progress of smear positive patients on chemotherapy must be monitored by
sputum examination at regular intervals until the sputum is smear negative.

•
•

Multidrug regimens should be considered for people at high risk of severe forms
of disease who are likely to be infected with isoniazid resistant organisms.

•

Isoniazid chemoprophylaxis is contraindicated for people with chronic liver
disease or alcoholism. Where there is doubt long term surveillance is
recommended.

Patients who have had at least six months of supervised chemotherapy for TB
should not be routinely followed for longer than three years after treatment is
completed. They should be given a copy of their latest chest x-ray and advised
about TB symptoms and urged to seek medical care immediately if symptoms
appear.

•

Active TB in HIV seropositive and other immunocompromised people should be
treated with conventional medications but for three months longer than for
other patients, or a minimum of six months after sputum cultures become
negative. Follow up of HIV-AIDS patients should continue indefinitely6 •

•

intravenous drug users

•

people with chest x-rays suggestive of inactive TB in whom active
disease is excluded and who have not completed treatment for TB

•
•

others under 45 years of age (including migrants/ refugees and residents
of long term facilities with no other risk factors).

•

People receiving chemoprophylaxis must be reviewed at least monthly for side
effects and to assess compliance.

•

Chemoprophylactic drugs have side effects and are potentially toxic. The
benefits of treatment must be weighed against the risks and costs, and the
decision for treatment must be individually assessed.

i

I
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c.

GUIDELINES FOR HOSPITALISATION OF ACTIVE CASES

PATIENT MANAGEMENT

Isolation procedures

A.

INTRODUCTION

People with direct sputum smear positive TB should be treated with
appropriate anti-TB drugs in a single room for at least two weeks. Acid
fast bacilli (AFB) precautions should be continued until the AFBs are
clearing from sputum specimens and there is a significant clinical
improvement.

•

People with infectious TB should be isolated from immunocompromised
persons, until sputum is negative for AFB or no sputum is being
produced.

Transmission of infection is more likely to occur in poorly ventilated and
overcrowded conditions, and infection of family contacts is the most
common. The risk of infection is related more to the bacteriological
status of the patient rather than to the intimacy of contact, so that
infection may occur when contact has not been prolonged or close.

•

B.

•

•

Indirect contact through contaminated articles is extremely rare, as is
direct invasion through mucous membranes or breaks in the skin.

•

Appropriate antimicrobial therapy reduces communicability within a few
weeks; some untreated or inadequately treated patients may be
intermittently AFB sputum positive for years.

•

Single rooms, with external ventilation (negative pressure), are
necessary for people with infectious TB. Patients may leave their rooms
and use hospital grounds.

•

Closed extrapulmonary TB is not infectious. There is a risk of
transmission in the presence of a tuberculous discharge.

•

The following equipment is needed for each room: masks, thermometer,
garbage bag holder with contaminated waste bag.

•

The followiing additional equipment is needed if a discharging lesion or
sinus is present: plastic aprons/gowns and disposable gloves.

•

Separate crockery, cutlery and bed linen are not required, as tubercle
bacilli do not survive for long outside the body and are killed by normal
machine dishwashing and laundering procedures.

•

Soiled linen should be treated as contaminated.

HOSPITAL ADMISSION

•

Patients diagnosed or suspected of having active TB should be admitted
to hospital to:
•

•

confirm the diagnosis,

•

mm1m1se further spread
communicability, and

during

the

period

of

high

•

initiate the treatment and assess the patients' tolerance of
medication.

Patients with active TB should remain in hospital as long as their
sputum is positive for AFB on direct examination. Three specimens
collected at 24 hour intervals should be negative for AFB. Exceptional
circumstances may justify earlier discharge. A longer time in hospital
may be required under the following circumstances :

•

continued infectivity due to severe disease with cavitation or
medication failures, or

•

social situation that may lead to non-compliance and disease
transmission.

44

Personal hygiene

•

Patients should be instructed in personal hygiene especially the need to
cover the mouth and nose when coughing or sneezing and the careful
handling and disposal of sputum.

Waste Disposal
•

Sharps should be disposed as usual.

•

Sputum should be collected in disposable containers, with lids which can
be SECURED.

•

Patients should be instructed to cough and sneeze into tissues, which
should be disposed of in plastic bags .

•

Body Substance Isolation Precautions apply as normal to handling of
urine etc.

45

Laboratory Specimens

•

•

E.

STAFF PROTECTION

Laboratory specimens should be:

•

•

well sealed with no contamination of the outside of the bottle,

•

transported immediately to laboratory in a sealed biohazard bag.

•
A yellow sticker should be placed on the request form which is placed in

the separate sleeve of bag.

Staff involved in the management of diagnosed cases of tuberculosis are
at no greater risk of contracting the disease than other staff in
hospital. In fact, there is a greater risk of contracting tuberculosi:
from undiagnosed cases.
All medical and nursing staff, as well as pathology, radiology and
paramedical staff in a hospital should have a Mantoux test at the
beginning of employment, and be offered B.C.G. vaccination if Mantoux
negative.

Visitors

•

•

Visitors should wash hands on entering and leaving the room .

•

Visitors do not need to wear gowns or masks.

•

•

Children other than the patient's own children should be discouraged
from visiting.

•

Transport of Patients

•

Patients should be adequately clothed, and required to wear a mask only
to cover mouth and nose with tissue while coughing or sneezing.

Mantoux negative staff on wards with active cases of TB should have
regular screening with Mantoux tests (see Chapter 3.4).
Staff should be screened according to routine contact tracing procedures
after exposure to potentially infectious cases of TB for whom adequate
infection control measures had not been taken.
Universal precautions should be taken. Specifically:

•

TB patients' rooms should be cleaned daily with neutral detergent and a
disposable cloths. The disposable cloths should be discarded as
contaminated waste.

•

TB patients' rooms should be cleaned after other rooms have been
attended.

,,

I'
,,

•

Cleaning of Room

D.

•

Immunocompromised staff members should not work on wards where
there are active cases of TB.

•

Masks should be put on when patient requires close nursing
attention only.
Body substance isolation precautions apply when handling
sputum or other infected body substances.

NOTIFICATION OF CASES
•

Tuberculosis is notifiable under the Public Health Act 1991. It is
notifiable as tuberculosis by Medical Practitioners pursuant to Section
14, by Hospital Chief Executive Officers pursuant to Section 69 and as
mycobacterial infection by laboratories pursuant to Section 16 of the Act.
Notifications must be made to the Public Health Unit using Notifiable
Disease certificates which are available from the Public Health Units.

•

The TB sister at the Chest Clinic serving the area where the patient
lives, should be contacted as soon as possible after admission, and
certainly before discharge, to discuss arrangements for supervision of
post discharge treatment of the patient and examination of contacts.

•

All patients should have supervised chemotherapy
hospitalisation and after discharge from hospital.

46
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BACTERIOLOGICAL STUDIES IN TUBERCULOSIS29

3.13

B.

The ultimate success of any modern TB Control Program will be conti~gent on the
availability of high quality laboratory services. Important functions of the
mycobacteriology laboratory are:

•
•
•
•
•
•
•

A.

It is essential that laboratories performing diagnostic mycobacteriology at any level
carry current NATA accreditation for such procedures by NATA. In addition, there
should be continued efforts to monitor proficiency through participation in quality
assurance programs (QAP) such as those conducted by the following:

microscopy
culture
speciation of isolates
drug susceptibility testing
statistics
training
research

•
•

The major of Australian pathology laboratories subscribe to the RCPA Microbiology
QAP, which regularly includes a test for a laboratory's capability to demonstrate (and
recogiuse) mycobacteria in specimens and in cultures. It must be stressed that
satisfactory completion of this exercise should not be taken as proof of proficiency in all
facets of mycobacteriology. The RCPA QAP does, however, contribute to the general
awareness of mycobacteria as pathogens.

Obviously, not all pathology laboratories need to provide such services. US au~horities
have proposed a three tiered 'classification' sys~em . for labs carrymg out
mycobacteriological tests. Australian labs can be categonsed m much the same way, as
set out below.

Level II

Level III

RCPA (Royal College of Pathologists of Australia)
CAP (College of American Pathologists)
ASM (Australian Society for Microbiology)
State Tuberculosis Reference Laboratories.

•
•

Level of laboratory service • mycobacteriology

Levell

. Quality assurance

C.

This category covers the majority of 'general' bacteriology ~abora~ories (~s
would be found in hospitals) and smaller private pathologists. Direct acid
fast microscopy (AFM) should be available, but culture for MTB should
not be attempted. Specimens are referred to a higher level facility for
both confirmatory microscopy as well as culture.

Standards

It has been a goal of the Special Interest Group in Mycobacteriology (within the
Australian Society for Microbiology) to standardise methods in use in major diagnostic
mycobacteriology labs throughout Australia. Although some degree of success can be
claimed, each of the reference labs have long established protocols, and most are
reluctant to make major changes. Nevertheless, it can be said that methods in use are
similar and have comparable sensitivity and outcome, as shown by the results of
collaborative trials.

This category covers the larger laboratory as would be found in certain
metropolitan and provincial hospitals, and some private patholo_gy
laboratories·. Such facilities perform both AFM and mycobactenal
culture. Species identification is not generally performed at this Level,
although this situation might change due to new technology such as
radiometric culture and DNA probes. Even so, it is imperative that all
new isolates of MTB as well as any likely pathogenic atypical
mycobacteria be forwarded to a Level III facility for further testing.

Microscopy
Should be performed on all specimens (blood would be optional), using Ziehl-Neelsen
and/or fluorochrome staining. Positive reports should make some attempt quantitation
of the number of AFB present.

Laboratories in this category will generally be large reference units such
as now exist in Brisbane, Sydney, Melbourne, Adelaide and Perth. In
addition to AFM and culture, Level III labs provide drug susceptibility
tests, and full speciation of isolates. Support should also be available to
lower level labs in the form of training, provision of reference methods
and mycobacterial strains. Statistics, particularly those dealing with new
diagnoses of TB, should be collated and provided to public health
authorities. Level III labs should also be involved in the development or
evaluation of new tests such as those involving molecular procedures. In
the future, seruni drug assays might be performed on patients being
treated for certain atypical mycobacterial infections.
·

Culture
Should be performed on all specimens, using either the BACTEC system, or egg based,
or agar media or combinations of these. Certain species such as M bovis, M
haemophilum, M marinum have special requirements in media and/or temperature of
incubation, and must be adequately catered for. BACTEC 13A medium is
recommended for blood cultures. All cultures should be read at least weekly for at
least 6 weeks.
Identification
Level III facilities should have the expertise to identify all human pathogens.

Note: It would be the opinion of most expert mycobacteriologists that culture should ~ot be undert~ken in
situations where the number of samples received is small, and/or the frequency of pos1t1ves (MTB) 1s v~ry
low. In such situations, quality assurance procedures assume greater importa~ce. As a gmde, laborato1:es
receiving Jess than around 40 routine samples per week should be discouraged from performing
mycobacterial culture. There would be exceptions, e.g. in the case of a laboratory dealmg with regular
requests for blood culture in patients with AIDS.

•

MTB Complex: identify by recogiused criteria, such as niacin
production, nitrate reduction, cord formation, lack of growth at room
temperature, drug susceptibility. Differentiation within the MTB
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complex can also be achieved through such tests. Commercial DNA
probes can provide more rapid results and are acceptable substitutes,
but will not provide speciation within the MTB complex.
•

Atypical Mycobacteria: identify all isolates likely to be pathogens, i.e.
repeat isolates from sputum, isolates from sterile sites, tissues,
wounds. Authoritative texts provide adequate reference sources fro
procedures and identification strategies.

Susceptibility
Should be performed only in Level III facilities.

•

•

D.

APPENDIX 1 CASE DEFINITIONS

TUBERCULOSIS
Tuberculosis is notifiable under the Public Health Act 1991 It ·
tifiabl
tb cul· b Mdial
. 1sno
eas
u er . os1s Y e c Practitioners pursuant to Section 14, by Hospital Chief
Executiv~ Officers pursuant to Section 69 and as mycobacterial infection b
laboratories pursuant to Section 16 of the Act. Tuberculosis case d fi ·t· Yao
follows :
e m 10ns are as

Clinical Criteria

MTB complex: test all initial isolates, as well as repeat isolates from
relapse cases and 'treatment failures', for susceptibility to at least
isoniazid, ethambutol, rifampicin and pyazinamide. The radiometric
(BACTEC) method is recommended.

•
•

Atypical Mycobacteria: The value of susceptibility tests on a lowgrowing atypical mycobacteria remains a topic of debate, although it is
likely that more conclusive data will emerge in the near future. As a
general policy, drug susceptibility testing of slow-growing species such
as M avium comJJlex cannot be justified. Some species (e.g. M kansasii)
are so uniform in their susceptibility patterns that there is nothing to
be gained from testing every isolate. Rapid growing species such as M
fortuitum should be tested against a range of drugs such as
tetracyclines, aminoglycosides, sulphonamides, by disc diffusion or disc
elution.

The new DNA amplification procedures such as PRC promise to revolutionise
diagnostic mycobacteriology. Numerous publications have demonstrated the potential
value of such assays, but they remain unproven in prospective clinical studies.
Commercial PCR based tests for mycobacteria are likely to be released in the near
future. Potentially, these will offer further opportunity for the smaller lab to perform
high level mycobacteriology, and might bring about further change in
recommendations as to which laboratories perform what tests.
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Signs and symptoms compatible with extrapulmonary tuberculosis, or

•

Evi~ence of disease where treatment, with two or more
antituberculous medications, has been prescribed.

Laboratory Criteria

•
•

Technological developments in mycobacteriology

The development of the semiautomated radiometric technique (BACTEC) has been
partly responsible for a trend towards decentralisation of mycobacteriological
laboratory services. Data accumulated from numerous centres in the past decade has
confirmed its reliability, sensitivity, and reproducibility. A noteworthy virtue of the
BACTEC system is that it provides a safe, efficient procedure for culturing blood from
patients infected with HIV. It also includes options for (i) rapid differentiation of MTB
complex and atypical mycobacteria (4 days), and (ii) rapid determination of drug
susceptibility (4-7 days). Further, commercial probe kits can be applied directly to the
BACTEC cultures for speciation. Thus, BACTEC can shorten significantly the interval
between receipt of specimen and issue of results.

Signs and symptoms compatible with pulmonary tuberculosis with an
abnormal, unstable chest x-ray, or
'

Isolation of Mycobacterium tuberculosis, Mycobacterium bovis or
Mycobacterium africanum from a clinical specimen, or
Demonstration of acid fast bacilli in clinical specimen when a culture
h_as not been or cannot be obtained, in a person suspected of having
signs and symptoms compatible with tuberculosis 3 1.

NEW/ CHRONIC/ REACTIVATED CASES

Relapse or reactivation

•

Proven clinic~ly, radiologically or bacteriologically following at least
12 months. qUie~cence after full chemotherapy has stopped and cure
was bactenologically proven.

New case

•

Never received antiTB treatment for more than one month .

Treatment failure

•

Still direct smear positive at five months or more after the start of
chemotherapy for a newly diagnosed case of TB.
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APPENDIX 2 MINIMUM DATA REQUIREMENTS FOR TB CASE FINDING
AND MANAGEMENT
Returning defaulter

•

•

age, sex, body weight

•

date of onset, date of diagnosis, date of notification

•

Chest Clinic/ AHS or Region - commencing treatment/ supervising treatment

•

postcode of residence

•

ethnicity - Asian, Australian Aboriginal, Caucasian, Pacific Islander, Other

•

immigration status - refugee, SHP, etc

•

country of birth, length of residence in Australia - date of arrival

•

HIV status - PIN/lJ; BCG status - YIN/lJ

•

diagnosis - microscopy (PIN), culture (PIN), Mantoux tests (mm, PIN), other
skin test (mm, PIN), histology (PIN), radiological signs, clinical signs, other

•

pathogen

•

site of disease - Pulmonary/ Extrapulmonary/ Both - pulmonary, pleurisy with
effusion, pericarditis, peritonitis, laryngeal/ endobronchial, lymphadenitis,
skeletal, genitourinary, meningeal, ocular, gastrointestinal, adrenal, cutaneous,
miliary, other

•

past history of disease and anti-TB treatment - new case/ relapse/
treatment failure/ returning defaulter/ chronic case (see Appendix 1 for
definitions); previous anti-TB treatment - Y (one or more months)/ N - dates
commenced, stopped, completed

•

refugee screening program/THU - attended initial visit, attended follow ups,
follow up completed - dates

•

source of diagnosis - chest clinic (self referral), hospital, specialist, GP, TBU,
refugee screening program etc; transfer - YIN

•

medications (15 possibilities plus 3 other) - dates initiated and completed codes for standard regimens eg 2HRZ/4HR3; supervision - YIN

•

drug sensitivities - four drugs

•

treatment outcome - bacteriology smear results - dates; regularity of drug
intake - interruption of therapy, resumed therapy, ceased therapy, lost to follow
up - dates; died during treatment - YIN - cause of death TB or other (see
Appendix 1 for definitions)

•

contacts - relational file; other public health action

Interrupted treatment for more than 2 months after completing the
first month of chemotherapy, returned to treatment and was found to
be direct smear or culture positive.

Chronic case

•

Still discharging AFB after completing a retreatment regimen under
supervision.

CAUSE OF DEATH
Deaths caused by TB
•

Principal cause of death was TB.

Deaths contributed to by TB

•

Principal cause of death is not TB but TB may be a contributing factor .

Deaths incidental to TB

•

Principal cause of death was not TB, but TB was present at time of
death.

I

52

53

!

J

APPENDIX 3 SURVEILLANCE AND PROGRAM EVALUATION INDICATORS

I»1:ection data are obtained from Mantoux screening. Screening serves a number
of unportant roles, by providing:

•

Monitoring active disease

A.

•
,,
i',j

I
,,

In prac~ce there are limitations to the monitoring of TB infection in the general
populat10n because: .
.

•
•

TB-HIV coinfection rates - Although TB-HIV coinfection does not
appear to be a problem in NSW at present, there is a need to carefully
monitor the situation.

•

•

TB mortality rates - The value of mortality data as an indicator of
the TB problem is limited in industrialised countries because effective
32
chemotherapy has vastly reduced deaths from TB • Careful analysis of
mortality trends, however, contributes to the monitoring of diagnostic
and treatment standards.

•

TB meningitis incidence rates in children under 5 years of age This is a useful indicator of the intensity of M tuberculosis
transmission and thus also of the effectiveness of case finding and
treatment32 • It is also important as a measure of the need for BCG
vaccination of neonates.

!

.'

•

B.

•

Smear positive active TB incidence rates - Smear positive cases
provide the most important epidemiological information because smear
positive cases are the most infectious; they provide a highly specific
core index of cases diagnosed with certainty; they are the most globally
comparable; and case holding and treatment outcomes of
these
32
patients provides the best measures of program efficacy •

•

''

•
•

Active TB incidence rates - Age, sex and ethnicity specific rates
should be estimated, particularly active TB incidence rates in children
less than five years of age.

Drug resistance rates - Drug sensitivity testing for primary and
acquired resistance provides useful information not only on the
epidemiological situation, but also on the effectiveness of the
treatment program.

epi~e~iologic data for assessing the extent of the TB problem (and
penodi~ surv~ys provide trends of infection in the population),
data with which to assess the value of continued screening
identification of people who would benefit from prophylacti~ or curative
therapy, and,
the opportunity to increase the awareness of high risk populations
about TB and how to access TB Services.
·

•
•

•

•

c.

significant resources are required,
large sample sizes are needed in low prevalence populations to obtain
reliable estimates,
the predictive value of screening tests declines with decreasing
prevalence,
in terms of ide~ti~ng individuals who would benefit from prophylactic
therapy screerung 1s only productive and cost effective in populations
with a high prevalence ofTB 6 , and
B~G vac~nati?n ~~ make the Mantoux test difficult to interpret and
ummmumsed individuals may not be representative of the general
population.

Mantoux conversion rates in contacts - This reflects the current
transmission of TB in the population.

Evaluating case finding and management'

•

Case detection ratio · Proportion of expected cases that were
rep.ort~d. This reflects the intensity and the extent of the case finding
activities. The calculation requires prior knowledge of the annual risk
of infection; it may not be valid when the annual risk of infection is
low"'.

•

Delay in diagnosis - Time after onset until diagnosis .

•

Delay until treatment - Time after diagnosis untii treatment
commenced.

Monitoring infection

•
•

Annual incidence (or risk) of infection - Direct estimates require
periodic screening of cohorts of unvaccinated people.
Infection prevalence - Prevalence estimates among unvaccinated
children, from Mantoux testing surveys, can be used to derive a crude
estimate of the risk of infection in the population.

CaJeulation of tb~ indicators .by coho~ anaJy~is i9 the most infomtBtive (or evaluating the case holding and treatment program. The
cohort ~houl~ consist of aJI pat1e11ts registered 1n a given ti.Ine i.tat.fi!rval (eg three or 12 months). Tb1:1c duration of the interval between
~he i~Stl'8~1on of the cases an~ the a~alysis is cb.osen so that all patients can have completed the pregcribed treatment and foUow·
JI formation bas become avruJable (re the duration of the treatttaent regi!Jlen plus another three tnontbs).
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•
•

•

Appropriate drug regimen ratio · Proportion of active cases
initiating treatment with appropriate and/ or standardised multidrug
regimen.

Evaluating case prevention
Screening of contacts

Supervised therapy ratio · Proportion of active cases on supervised
therapy.

•

Bacteriologic conversion ratio · Proportion of cases with
bacteriologic conversion of sputum within three months of commencing
therapy33•

Delay in contact · Time from index case diagnosis until close contacts
examined.

•

Follow up ratio · Proportion of contacts examined.

•

Infection rate · Proportion of located contacts with new infections .

Drug continuity ratio - Proportion of active cases who have taken
chemotherapy continuously for the first six months of treatment;
Proportion interrupted therapy; Proportion stopped therapy33 •

•

Drug completion ratio - Proportion of active cases completing
therapy within six/ nine/ 12 months32 33•

•

•

Treatment failure ratio - Proportion who are still sputum smear
positive at five months or more after the start of chemotherapy32•

Screening of other high risk groups

•

Defaulter ratio - Proportion who interrupted treatment for more than
two months after completing one month of chemotherapy, returned to
treatment and were faun d to b e smear pos1't'1ve32.

•

•

•

Cure ratio . Proportion of patients whose cure was bacteriologically
documented. This is considered the best and most accurate indicator of
treatment program perlormance32 • A high cure ratio indicates that
both bacteriological follow up was properly done and that sputum
conversion occurred.
Relapse rates . Proportion of cases who have been previously declared
cured (bacteriologically) after completing full treatment more than 12
months before.

•

Case fatality ratio - Proportion of patients who died of any cause
during the course of treatment. It is an indicator of the perlormance of
the treatment program but also obviously provides information on the
TB problem32• However, it should be interpreted carefully in low
incidence countries.

•

Case finding and chemotherapy 'impact' indicators 34 :

•
•
•

Prophylactic therapy ratio · Proportion of contacts with new
infections who are prescribed prophylactic treatment.
Active disease prevalence - Proportion of located contacts with active
disease.

Infection prevalence · Proportion of various populations with infections
detected by screening.
Prophylactic therapy ratio - Proportion with infections who are
prescribed prophylactic treatment.
Active disease prevalence · Proportion with active TB disease detected
by screening.

Chemoprophylaxis

•

•

Drug continuity ratio · Proportion completed six continuous months of
medications
Supervised therapy ratio - Proportion on supervised therapy

A summary 'impact' indicator can be calculated from the four
indicators:
new cases diagnosed

new cases put on CT

treatment completed

cases rendered negative

cases put on treatment

treatment completed

IMPACT - ·-------··--·------·--· • --------·-------------existing cases

new cases diagnosed
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Figure 13 ·. TB Surve1·uance and Program Evaluation
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LEGAL ASPECTS OF TUBERCULosrs CONTROL
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Public Health Orders

"'
•

'

'

•

.Q-

I

Public health orders may he made under Part 3, Division 6 of the Public
Health
1991is:by an authorised Medical Practitioner ifs/he is satisfied
that theAct
person

•!

I

i

'

'

•
•

'

•

a

J>

suffering from tuberculosis and
is behaving in a way that is endangering, or is likely to endanger,
the
health of the public because the person is suffering from the
disease.

A public health order must require the person to whom it applies to do
any one or more of the following:

..;

6,
')>

"'rn
"'

-

-

'

'

-

T

•

refrain from a specified conduct

•

undergo specified treatment

•

undergo counselling by a specified person or by one or more
persons belonging to a specified class of persons

•

submit to the supervision of a specified person or one or more
persons belonging to a specified class of persons

-,

1

•

za

~

•

undergo specified treatment and be detained at a specified place
while undergoing the treatment.

An order must indicate:

0
:,:,

"'

-

--

I

t

-,
•

•

•

-

•

"';;,;

•

•

the circumstances Purporting to justify making the order and

•

the length of time it is to remain in force (up to 28 days).

Where the circumstances justify continuing the order past 28 days, than
an
application
be made to the District Court to extend the order for
up to
a further may
six months.
It is an offence to contravene an order and the person may be
apprehended by the police for such a contravention.
It isorder.
also an offence to improperly release a person being detained under
an

An appeal to the District Court may be made against the order.
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